GlaxoSmithKline Pharmaceuticals Ltd. (GSK India) reported a net profit growth of 3.3% to of ₹255 crore for the quarter ended September 30, 2025, despite seasonal and supply chain challenges.
Revenue from operations stood at ₹974 crore, reflecting a temporary topline dip due to GST-related transitions, seasonal disruptions, and a fire at a contract manufacturing site that impacted supply of select general medicines brands.
The company’s EBIDTA margin expanded by 250 basis points to 34.4%, driven by improved gross margins and operating leverage.
GSK’s core portfolios outperformed the market. Promoted brands in general medicines posted an Evolution Index (EI) above 100, indicating market share gains. The vaccines business maintained leadership in the self-pay paediatric segment, while adult immunization saw strong uptake of Shingrix, its herpes zoster vaccine.
The quarter also marked GSK India’s entry into oncology with the launch of Jemperli (dostarlimab) and Zejula (niraparib), targeting gynecological cancers. The company said the therapies have been well-received by healthcare professionals,.
“Within two months of launch, our oncology portfolio is already addressing critical unmet needs in women’s cancer care,” said Bhushan Akshikar, Managing Director, GSK India. “We remain committed to making innovative treatments accessible through robust patient support and financing initiatives.”
GSK India said it is proactively addressing supply chain issues and remains focused on sustaining growth momentum across portfolios.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
